The current financial score of Stoke Therapeutics Inc is 6.32. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 11.26M, representing a year-over-year increase of 5.86%, while its net profit experienced a year-over-year increase of 92.05%.
The current valuation score of Stoke Therapeutics Inc is 7.67. Its current P/E ratio is -9.33, which is -679.19% below the recent high of 54.03 and -3336.40% above the recent low of -320.57.
The current earnings forecast score of Stoke Therapeutics Inc is 8.86. The average price target is 46.92, with a high of 60.00 and a low of 35.00.
The current price momentum score of Stoke Therapeutics Inc is 3.81. Currently, the stock price is trading between the resistance level at 28.70 and the support level at 24.39, making it suitable for range-bound swing trading.
The current institutional shareholding score of Stoke Therapeutics Inc is 10.00. The latest institutional shareholding proportion is 118.29%, representing a quarter-over-quarter decrease of 3.39%.
The current risk assessment score of Stoke Therapeutics Inc is 6.37. The company's beta value is 1.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.